{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:25Z","timestamp":1787020765499,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01606-w","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:15:40Z","timestamp":1726762540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Marion","family":"Alcantara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Chevrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Peyrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kh\u00ea","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Soussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"7","key":"1606_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leuk Juill. 2022;36(7):1720\u201348.","journal-title":"Leuk Juill"},{"issue":"7","key":"1606_CR2","first-page":"869","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 18 f\u00e9vr. 2016;127(7):869\u201381.","journal-title":"Blood 18 f\u00e9vr"},{"key":"1606_CR3","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H et al. Molecular and clinical diversity in primary central nervous system lymphoma. Annals Oncol 2023 Feb;34(2):186-199.","DOI":"10.1016\/j.annonc.2022.11.002"},{"issue":"1","key":"1606_CR4","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","volume":"13","author":"J Radke","year":"2022","unstructured":"Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 10 mai. 2022;13(1):2558.","journal-title":"Nat Commun 10 mai"},{"key":"1606_CR5","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H, Soubeyran P, Chinot O, Taillandier L et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 6 janv. 2020."},{"issue":"11","key":"1606_CR6","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol Nov. 2017;4(11):e510\u201323.","journal-title":"Lancet Haematol Nov"},{"issue":"10","key":"1606_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"01","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;01(10):823\u201333.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leuk Juill. 2022;36(7):1870\u20138.","journal-title":"Leuk Juill"},{"key":"1606_CR9","doi-asserted-by":"crossref","unstructured":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients Age 60 years and younger: long-term results of the Randomized phase II PRECIS study. J Clin Oncol. 2022; Nov 10;40(32):3692-3698","DOI":"10.1200\/JCO.22.00491"},{"issue":"6","key":"1606_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41409-022-01648-z","volume":"57","author":"L Schenone","year":"2022","unstructured":"Schenone L, Houillier C, Tanguy ML, Choquet S, Agbetiafa K, Ghesqui\u00e8res H, et al. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone Marrow Transpl juin. 2022;57(6):966\u201374.","journal-title":"Bone Marrow Transpl juin"},{"issue":"S2","key":"1606_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.3163_15","volume":"41","author":"G Illerhaus","year":"2023","unstructured":"Illerhaus G, Ferreri A, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, et al. Consolidative HCT-ASCT is superior to non\u2010Myeloablative Chemo\u2010IMmunotherapy in Newly\u2010Diagnosed Pcnsl \u2010 Updated Results of the Randomized Phase III MATRIX\/IELSG43 Trial. Hematol Oncol juin. 2023;41(S2):41\u20133.","journal-title":"Hematol Oncol juin"},{"issue":"9","key":"1606_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/neuonc\/now033","volume":"18","author":"S Langner-Lemercier","year":"2016","unstructured":"Langner-Lemercier S, Houillier C, Soussain C, Ghesqui\u00e8res H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol Sept. 2016;18(9):1297\u2013303.","journal-title":"Neuro Oncol Sept"},{"key":"1606_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u00ab proof-of-concept \u00bb iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"key":"1606_CR14","doi-asserted-by":"publisher","first-page":"112909","DOI":"10.1016\/j.ejca.2023.04.025","volume":"189","author":"C Soussain","year":"2023","unstructured":"Soussain C, Malaise D, Choquet S, Ghesqui\u00e8res H, Houillier C. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) network (clinical trial number: NCT02542514). Eur J Cancer ao\u00fbt. 2023;189:112909.","journal-title":"Eur J Cancer ao\u00fbt"},{"issue":"4","key":"1606_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"01","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molu\u00e7on-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u00ab proof of concept \u00bb phase II study of the French Oculo-cerebral lymphoma (LOC) network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol. 2019;01(4):621\u20138.","journal-title":"Ann Oncol"},{"key":"1606_CR16","doi-asserted-by":"crossref","unstructured":"Alcantara M, Fuentealba J, Soussain C. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. Cancers. oct 2021;10(20):5061.","DOI":"10.3390\/cancers13205061"},{"issue":"6","key":"1606_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by Ibrutinib in primary CNS Lymphoma. Cancer Cell 12 juin. 2017;31(6):833\u2013e8435.","journal-title":"Cancer Cell 12 juin"},{"key":"1606_CR18","doi-asserted-by":"crossref","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 1 ao\u00fbt. 2005;23(22):5034\u201343.","DOI":"10.1200\/JCO.2005.13.524"},{"issue":"28","key":"1606_CR19","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 1 oct. 2006;24(28):4570\u20134.","journal-title":"J Clin Oncol 1 oct"},{"issue":"6","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol juin. 2015;2(6):e251\u2013259.","journal-title":"Lancet Haematol juin"},{"issue":"9","key":"1606_CR21","first-page":"1403","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 26 f\u00e9vr. 2015;125(9):1403\u201310.","journal-title":"Blood 26 f\u00e9vr"},{"issue":"4","key":"1606_CR22","first-page":"846","volume":"31","author":"K Fritsch","year":"2017","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, M\u00f6hle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leuk avr. 2017;31(4):846\u201352.","journal-title":"Leuk avr"},{"issue":"2","key":"1606_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JEC Bromberg","year":"2019","unstructured":"Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol f\u00e9vr. 2019;20(2):216\u201328.","journal-title":"Lancet Oncol f\u00e9vr"},{"issue":"5","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol Mai. 2016;3(5):e217\u2013227.","journal-title":"Lancet Haematol Mai"},{"issue":"4","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3324\/haematol.2022.282014","volume":"108","author":"A Suleman","year":"2023","unstructured":"Suleman A, Liu J, Hicks LK, Drori AK, Crump M, Kridel R, et al. Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. Haematol 1 avr. 2023;108(4):1186\u20139.","journal-title":"Haematol 1 avr"},{"issue":"5","key":"1606_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.16451","volume":"189","author":"E Schorb","year":"2020","unstructured":"Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B\u2010cell lymphoma of the central nervous system \u2013 an international study of feasibility and efficacy in routine clinical practice. Br J Haematol juin. 2020;189(5):879\u201387.","journal-title":"Br J Haematol juin"},{"issue":"5","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood 31 janv. 2019;133(5):436\u201345.","journal-title":"Blood 31 janv"},{"issue":"22","key":"1606_CR28","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1002\/cam4.3499","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen F, Pang D, Guo H, Ou Q, Wu X, Jiang X, et al. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real\u2010world experience of off\u2010label ibrutinib use. Cancer Med Nov. 2020;9(22):8676\u201384.","journal-title":"Cancer Med Nov"}],"updated-by":[{"DOI":"10.1186\/s13045-024-01620-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000}}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01606-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01606-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01606-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T16:31:50Z","timestamp":1729355510000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01606-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01606-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-024-01620-y","URL":"https:\/\/doi.org\/10.1186\/s13045-024-01620-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with Good Clinical Practice, as defined by the International Conference on Harmonization and according to applicable regulatory requirements. The study protocol and all amendments were approved by the competent authority and independent ethics committee. All patients, or the persons on confidence in case the neurological status of the patient did not allow him to understand and\/or to sign, provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM performed scientific and medical consulting for Novartis, Janssen, Kite\/Gilead and MSD and received research grants from Mnemo Therapeutics. OL has received honoraria and travel fundings from Roche, Kite\/Gilead, BMS, Janssen and AstraZeneca. HR has received honoraria from Kite\/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and is a member on an entity\u2019s Board of Directors or advisory committees of Kite\/Gilead, Novartis, Bristol-Myers Squibb\/Celgene, ADC Therapeutics, Incyte and Miltenyi. SC received a research grant from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}